IRAK-1/4 Inhibitor I
SIGMA/I5409 - ≥98% (HPLC), solid
Synonym: 1-
CAS Number: 509093-47-4
Empirical Formula (Hill Notation): C20H21N5O4
Molecular Weight: 395.41
MDL Number: MFCD09752602
Linear Formula: C20H21N5O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white to light yellow |
| form | solid |
| InChI | 1S/C20H21N5O4/c26-19(15-4 |
| InChI key | QTCFYQHZJIIHBS-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | O=C(C1=CC([N+]([O-])=O)=C |
| solubility | DMSO: ≥5 mg/mL |
| storage temp. | 2-8°C |
| Application: | IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines. |
| Biochem/physiol Actions: | IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC50 values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested. |
| Biochem/physiol Actions: | IRAK-1/4 Inhibitor I is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4, with IC50 values of 300 nM and 200 nM for IRAK-1 and -4, respectively. |
| Biochem/physiol Actions: | IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit inhibitory effects on the nuclear factor (NF)-κB signaling pathway. |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | T |
| Risk Statements | 25-36/37/38 |
| Safety Statements | 26-36/37-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |

